Driving transformative patient/consumer-centric healthcare strategy and innovation. Championing availability, access & adoption of self-directed healthcare solutions for patients and consumers.Clients include prescription & non-prescription businesses; Fortune 500 & start-up ventures; Marketing & Advertising organizations.Synthesizing complexity to inspire brand-building growth with integrated commercial and regulatory strategies. Technology assisted patient / consumer access across prescription and non-prescription initiatives.• Enhancing healthcare brand adoption and retention with strategic solutions to address marketplace needs and behavioral barriers• Lifecycle management: novel marketing & regulatory strategies, product innovation, claims & technology• ACNU: Advancing solutions to deliver consumer/patient access through the FDA proposed ACNU rule (Additional Condition for Non-prescription Use)• Rx-to-OTC switch: best practice & key success factors; labeling & packaging; switch process & behavioral studies; benefit/risk assessment; cross-functional coordination; commercial business planning & brand launch

- Statistics, Measurement & Analysis. A graduate marketing course- Healthcare Product and Brand Development: From Discovery to Launch to Brand Building. An elective course in the Certificate in Healthcare Marketing and Communications- Statistics, Measurement & Analysis. A graduate marketing course

Head of marketing for US women's health portfolioBusiness / product innovation cross-functional lead for R&D, regulatory, and commercializationRx-to-OTC switch program lead (patient/consumer access initiatives): Opill - non-prescription daily oral contraception; ella - emergency contraceptionResponsible for development of two first-in-class US OTC contraceptive brand introductions, including both cross-functional lead for Rx to OTC switch development and brand commercialization strategy.• Led cross-functional team - regulatory, clinical, medical, marketing, supply, project management, CRO & KOL experts• Championed programs, significantly improving business cases & strategic definition• Generated thorough understanding of the patient journey and consumer path to purchase• Completed OTC labeling development and behavioral testing, clinical behavioral actual use studies• Guided numerous FDA interactions. strategy, briefing books, meetings written responses, labelling changes• Accelerated clinical study recruitment leveraging digital marketing & analytical expertise• Led HCP and NGO engagements, securing broad KOL, NGO & patient advocacy supportUS marketing responsibility: brand strategic development; integration and (re)launch plans for acquisitions; building marketing team; strategic retail sell-in; agency selection & management; advertising campaigns, executional excellence; budget management and forecasting. • Resourcefully directed strategy & execution: delivered portfolio turnaround and double digit e-commerce growth in competitive marketplace.• Transformed use of technology & analytics to both identify optimal communication touch points, and significantly boost digital & ecommerce plans.• Delivered substantial gains in media resonance & efficiency leveraging behavioral marketing & AI techniquesAs the first US employee, took a key role in establishing the US affiliate: business case, organization design and colleague identification.

Led commercial team of 10 and co-lead for cross-functional team of 70 colleagues for $4bn NPV portfolio of lifecycle management initiatives. Managed departmental resource prioritization and budget. Drove global vision, strategic development, environmental influence, retail engagement & commercialization planning. Established collaborative network, negotiated resources, navigated stakeholders across Pfizer business units, functions and brand teams. • Advanced 8 stage-gated global programs (including Lipitor, Viagra and Nexium)• Synthesized switch best practices for regulatory pathway progress and brand launch• Championed OTC Viagra Global Brand Strategy, including cross-discipline EU regulatory filing, resulting in highly successful EU launches & program awards.• Leveraged innovative digital & research tools to generate rich patient journey and HCP insights• Headed collaboration to fashion global brand guidelines & integrated launch planning toolkits• Crafted integrated communication plans to address both HCP & patient barriers for diagnosis, purchase & use.• Pioneered Lipitor Rx to OTC program: Secured FDA alignment for novel labeling resulting in compelling pivotal label comprehension, self-selection & use studies. Drove comprehensive public health rationale to address regulators, HCP’s, NGO & managed care dynamics. Defined OTC vision, brand strategy, packaging and consumer & HCP communication strategies.• Shaped public, KOL and NGO environment for OTC access: multiple advisory boards, publications, state legislation. Secured numerous endorsements for Lipitor and Viagra OTC switches.

Established Pfizer global Rx to OTC switch lifecycle management strategy and drove development of governance, switch processes & capabilities. • Gained corporate alignment for business case and strategy for Pfizer to pursue portfolio of first-in-class switch programs across multiple therapeutic areas: Established cross-business unit governance and collaboration. Secured approval for stage-gated investment scenarios. Drove portfolio evaluation and prioritization including identification of critical issues to be addressed specific for each program• Championed program to switch Lipitor, the world’s largest prescription brand: Led complex cross-business unit analysis, planning, issues management strategy and novel OTC labeling development. Resulted in successful pilot studies, positive end-of-phase 2 FDA feedback & organization buy-in to pursue program.

Led global acquisition, integration, international commercialization, forecasting, and A&P planning for ThermaCare medical device.• Delivered 150% international Thermacare sales growth across 9 markets within 2 years, including 3 new country launches.• Led global cross-functional team of over 100 people in acquisition & integration planning for ThermaCare• Rapidly synthesized consumer insights and messaging priorities to determine strategic imperatives• Drove ThermaCare re-launch strategic plan, content and creative campaign execution, inspiring collaboration across marketing teams in 11 countries• Led strategic evaluation for probiotics category adjacency entry for Centrum multivitamins franchise.• Implemented successful strategic planning & launch preparations for new probiotic supplement in Italy• Strategic assessments resulted in Ferrosan acquisition in Northern Europe

Responsible for International Analgesic, Respiratory & Personal care ~$500MM portfolio.• Accelerated 2003-2008 5 year sales CAGR from 1% to 8%. Championed international analgesic /Advil strategic vision and brand plans in highly competitive market. Inspired marketing teams across the globe in 17 Advil launches.• Crafted & secured alignment for Advil Global expansion and investment strategy. Established brand strategy and synthesized launch best practices. Steered local marketing plan execution, capabilities development & plan achievement.• Created best practice learning and compelling creative campaigns. Collaborated with local marketing teams to drive strategic launch/re-launch activities in over 15 international markets. Resulted in share gains and double-digit growth in markets across North America, Europe, Latin America and Asia. Established innovation strategy and directed new product development.• Recognized with 5 Global Marketing Excellence Awards: U&A research best practice, global analgesic consumer insight, comparative claims development, acquisition planning, and launch planning.

Progressed with roles of increasing responsibility to develop comprehensive strategy, pharmaceutical sales & technical consumer/HCP marketing skills with significant P&L and brand management responsibility. Held Corporate, Consumer and Pharmaceutical division positions in UK, France and US.US brand management: consistently exceeded performance and business growth expectations. Brand launch and turnarounds; driving share growth; advertising development and media planning; 7 successful line extensions; packaging innovation and novel patents; new product development, Rx-to-OTC Switch.Drove Rx to OTC switch programs; environmental modification and thought leader (KOL) development. • Brands: TUMS, Nicorette, Nicoderm CQ, Flonase, Gaviscon• Led the creation of SmithKline Beecham's first global marketing training program• Integral contributions to the analysis, acquisition and integration of Sterling Healthcare; responsible for 17 anti-trust filings; member of corporate integration team and led International business planning analysis post acquisition.• Pharmaceutical sales representative in California.